Belite Bio (BLTE) said late Wednesday it signed a securities purchase deal with a new healthcare investor to buy and sell 258,309 of its American depositary shares and warrants to buy equal amount of American depositary shares at $58.07 per ADS in a registered direct offering for gross proceeds of roughly $15 million.
The biopharmaceutical company intends to close the offering around Friday, and plans to use the net proceeds for working capital and general corporate purposes, it added.
Belite Bio's stock was down more than 1% in recent Thursday premarket activity.
Price: 57.11, Change: -0.96, Percent Change: -1.65
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。